Forest Laboratories, Inc. (NYSE: FRX) and H. Lundbeck A/S announced preliminary top-line results from a phase III study of LEXAPRO (escitalopram oxalate) in the treatment of adolescents, aged 12-17, with Major Depressive Disorder (MDD). [click link for full article]
Popularity: unranked [?]
